The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2019 | Hu5F9 plus rituximab to overcome resistance in refractory lymphoma
Lymphoma cells often use CD47 as a “don’t eat me” signal; if this antigen is blocked, the signal is removed and the lymphoma cell can be targeted by the immune system for autophagy. Here, Mark Roschewski of the National Cancer Institute, Bethesda, MD, discusses how the anti-CD47 antibody Hu5F9 can be used in combination with rituximab to overcome drug resistance in refractory lymphomas. This press briefing was recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
